AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$ARTV

Banerjee Subhashis sold $99K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 8,222 shares of Artiva Biotherapeutics, Inc. (ARTV) at $12.01 on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Aug 31, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine 10b5‑1 sale; market reaction is expected to be minimal.

02

Market read

Small insider sale with limited price impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical trial results or partnership announcements that could offset the sale impact.

Relevance 2/10Novelty 2/10Timing: post‑market 2026‑08‑27

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Chief Medical Officer sold 8,222 shares for $98,735, reducing his stake to 142,047 shares.

Expected impact

minor downward pressure, likely within normal volatility range

Evidence & confidence

Sale size is under $100k and represents a modest percentage of holdings; market typically discounts such routine 10b5‑1 sales.

Market effects

Sector

No immediate sector impact; biotech peers unlikely to be affected.

Regional

U.S. market only; no regional ripple.

Global

Limited global relevance.

Counterpoint

What could challenge this read

If the CMO is privy to upcoming positive data, the sale could be a pre‑emptive cash‑out before a catalyst.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Insider
    Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min